| The evolving druggability and developability space: chemically modified new modalities and emerging small molecules W Yang, P Gadgil, VR Krishnamurthy, M Landis, P Mallick, D Patel, ... The AAPS journal 22, 1-14, 2020 | 48 | 2020 |
| Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: Implications for biologics–small molecule drug interactions P Mallick, G Taneja, B Moorthy, R Ghose Expert opinion on drug metabolism & toxicology 13 (6), 605-616, 2017 | 48 | 2017 |
| Development and application of a life-stage physiologically based pharmacokinetic (PBPK) model to the assessment of internal dose of pyrethroids in humans P Mallick, M Moreau, G Song, AY Efremenko, SN Pendse, MR Creek, ... Toxicological Sciences 173 (1), 86-99, 2020 | 44 | 2020 |
| Population Life-course exposure to health effects model (PLETHEM): An R package for PBPK modeling SN Pendse, A Efremenko, CE Hack, M Moreau, P Mallick, M Dzierlenga, ... Computational Toxicology 13, 100115, 2020 | 22 | 2020 |
| Quantitative bias analysis of the association between subclinical thyroid disease and two perfluoroalkyl substances in a single study MW Dzierlenga, M Moreau, G Song, P Mallick, PL Ward, JL Campbell, ... Environmental research 182, 109017, 2020 | 15 | 2020 |
| Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice | 15* | 2015 |
| Impact of diet on irinotecan toxicity in mice P Mallick, P Shah, MM Ittmann, M Trivedi, M Hu, S Gao, R Ghose Chemico-Biological Interactions 291, 87-94, 2018 | 14 | 2018 |
| Using quantitative modeling tools to assess pharmacokinetic bias in epidemiological studies showing associations between biomarkers and health outcomes at low exposures ME Andersen, P Mallick, HJ Clewell III, M Yoon, GW Olsen, ... Environmental research 197, 111183, 2021 | 13 | 2021 |
| In vitro approaches to study regulation of hepatic cytochrome P450 (CYP) 3A expression by paclitaxel and rifampicin R Ghose, P Mallick, G Taneja, C Chu, B Moorthy Cancer Drug Resistance: Overviews and Methods, 55-68, 2016 | 12 | 2016 |
| Considerations for Improving Metabolism Predictions for In Vitro to In Vivo Extrapolation M Moreau, P Mallick, M Smeltz, S Haider, CI Nicolas, SN Pendse, ... Frontiers in Toxicology 4, 894569, 2022 | 11 | 2022 |
| Biological system considerations for application of toxicogenomics in next-generation risk assessment and predictive toxicology MB Black, A Stern, A Efremenko, P Mallick, M Moreau, JK Hartman, ... Toxicology in Vitro 80, 105311, 2022 | 10 | 2022 |
| Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro P Mallick, S Basu, B Moorthy, R Ghose Toxicology in Vitro 41, 75-82, 2017 | 10 | 2017 |
| Physiologically based pharmacokinetic modeling in risk assessment: case study with pyrethroids P Mallick, G Song, AY Efremenko, SN Pendse, MR Creek, TG Osimitz, ... Toxicological Sciences 176 (2), 460-469, 2020 | 9 | 2020 |
| Utilizing in vitro transporter data in IVIVE-PBPK: an overview P Mallick ADMET and DMPK 5 (4), 201-211, 2017 | 6 | 2017 |
| Effect of pentoxifylline on the pharmacokinetics of rosiglitazone in Wistar rats K Varanasi, S Potharaju, S Rajak, S Veeraraghavan, P Mallick, ... Methods Find Exp Clin Pharmacol 30 (7), 537-542, 2008 | 2 | 2008 |
| Effect of Pentoxifylline on the Pharmacokinetics of Nateglinide in Wistar Rat KVS Varanasi, SR Suresh Potharaju, S Veerraghavan, SPN Sivakumar, ... The Pharma professionals 1, 20-26, 2011 | 1 | 2011 |
| Role of Bacterial Translocation in the Progressive and Delayed Irinotecan-Induced Diarrhea BK Kee, S Gao, PK Chityala, SR Yu He J Clin Exp Pathol 8 (351), 2161-0681.1000351, 2018 | | 2018 |
| Effect of Cilostazol on Pharmacokinetics of Nateglinide in Wistar Rats P Mallick, SPN Sivakumar, SK VVS The Pharma Professionals 1 (2), 2011 | | 2011 |